UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 168

Sortiert nach

A review of trabectedin (ET-743): a unique mechanism of action

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2157-2163

2010

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2130-2143

2017

Link zum Volltext

Verfügbarkeit prüfen

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1623-1633

2017

Link zum Volltext

Verfügbarkeit prüfen

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Molecular cancer therapeutics, 2018-09, Vol.17 (9), p.1973-1983

2018

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2433-2440

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2018-04, Vol.17 (4), p.740-750

2018

Link zum Volltext

Verfügbarkeit prüfen

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.604-615

2012

Link zum Volltext

Verfügbarkeit prüfen

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers

Molecular cancer therapeutics, 2012-10, Vol.11 (10), p.2105-2115

2012

Link zum Volltext

Verfügbarkeit prüfen

A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1710-1722

2006

Link zum Volltext

Verfügbarkeit prüfen

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

Molecular cancer therapeutics, 2015-06, Vol.14 (6), p.1354-1364

2015

Link zum Volltext

Verfügbarkeit prüfen

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Molecular cancer therapeutics, 2019-10, Vol.18 (10), p.1875-1886

2019

Link zum Volltext

Verfügbarkeit prüfen

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2943-2950

2010

Link zum Volltext

Verfügbarkeit prüfen

The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

Molecular cancer therapeutics, 2006-07, Vol.5 (7), p.1800-1806

2006

Link zum Volltext

Verfügbarkeit prüfen

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Molecular cancer therapeutics, 2010-11, Vol.9 (11), p.2970-2981

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3186-3199

2010

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Molecular cancer therapeutics, 2005-09, Vol.4 (9), p.1378-1387

2005

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.959-967

2013

Link zum Volltext

Verfügbarkeit prüfen

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo

Molecular cancer therapeutics, 2010-12, Vol.9 (12), p.3254-3266

2010

Link zum Volltext

Verfügbarkeit prüfen

miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2265-2275

2010

Link zum Volltext

Verfügbarkeit prüfen

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth

Molecular cancer therapeutics, 2008-01, Vol.7 (1), p.110-120

2008

Link zum Volltext

Verfügbarkeit prüfen

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Molecular cancer therapeutics, 2015-01, Vol.14 (1), p.101-110

2015

Link zum Volltext

Verfügbarkeit prüfen

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

Molecular cancer therapeutics, 2013-10, Vol.12 (10), p.2200-2212

2013

Link zum Volltext

Verfügbarkeit prüfen

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1521-1530

2017

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic reversal of acquired resistance to 5-fluorouracil treatment

Molecular cancer therapeutics, 2009-05, Vol.8 (5), p.1045-1054

2009

Link zum Volltext

Verfügbarkeit prüfen

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.452-463

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 168

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaAntineoplastic Agents - Pharmacology

ThemaDrug Resistance

Zeitschrift / SerieMolecular Cancer Therapeutics

ThemaCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(168)

Publikationsform

Artikel
(168)

Sprache

Englisch
(168)
Japanisch
(168)

Erscheinungsjahr

n.n

Thema

Oncology
(168)
Life Sciences & Biomedicine
(163)
Science & Technology
(163)
Humans
(160)
Cell Line, Tumor
(112)
Animals
(86)
Mice
(74)
Drug Resistance, Neoplasm
(69)
Drug Resistance, Neoplasm - Drug Effects
(59)
Drug Resistance, Neoplasm - Genetics
(52)
Female
(52)
Xenograft Model Antitumor Assays
(49)
Apoptosis - Drug Effects
(43)
Cell Proliferation - Drug Effects
(34)
Gene Expression Regulation, Neoplastic - Drug Effects
(34)
Mice, Nude
(27)
Protein Kinase Inhibitors - Pharmacology
(27)
Male
(25)
Cell Survival - Drug Effects
(24)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(168)
Electronic Journals Library
(168)

Zeitschrift / Serie

Mol. Cancer Ther
(1)

Menü

Weitere Dienste

Einstellungen

A review of trabectedin (ET-743): a unique mechanism of action

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer

Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR -Mutated Non-Small Cell Lung Cancer

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers

A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats

The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax)

The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo

miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Epigenetic reversal of acquired resistance to 5-fluorouracil treatment

Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3

Aktive Filter

Suchergebnisse filtern